(S)-Lansoprazole

Modify Date: 2024-01-04 11:58:53

(S)-Lansoprazole structure	Common Name	(S)-Lansoprazole
	CAS Number	138530-95-7	Molecular Weight	369.36
	Density	1.5±0.1 g/cm3	Boiling Point	555.8±60.0 °C at 760 mmHg
	Molecular Formula	C₁₆H₁₄F₃N₃O₂S	Melting Point	N/A
	MSDS	N/A	Flash Point	289.9±32.9 °C

Use of (S)-Lansoprazole

(S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

Name	(S)-Lansoprazole
Synonym	More Synonyms

Description	(S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase Research Areas >> Inflammation/Immunology Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump Signaling Pathways >> Anti-infection >> Bacterial
References	[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [3]. Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487. [4]. Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. [5]. Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531(1-3):226-31.

Description

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump

Signaling Pathways >> Anti-infection >> Bacterial

References

[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.

[2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

[3]. Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487.

[4]. Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51.

[5]. Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531(1-3):226-31.

Density	1.5±0.1 g/cm3
Boiling Point	555.8±60.0 °C at 760 mmHg
Molecular Formula	C₁₆H₁₄F₃N₃O₂S
Molecular Weight	369.36
Flash Point	289.9±32.9 °C
Exact Mass	369.075867
PSA	87.08000
LogP	2.76
Vapour Pressure	0.0±1.5 mmHg at 25°C
Index of Refraction	1.635

Hazard Codes	Xn

S-(-)-LANSOPRAZOLE

(S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole

(S)-Lansoprazole

1H-Benzimidazole, 2-[(S)-[(1S)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-

LEVOLANSOPRAZOLE

2-[(S)-{[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl}sulfinyl]-1H-benzimidazole

(-)-Lansoprazole

Lansoprazole Impurity 15

(S)-Lansoprazole

Use of (S)-Lansoprazole

Names

(S)-Lansoprazole Biological Activity

Chemical & Physical Properties

Safety Information

Synonyms